Aluminum complexing enhances amyloid β protein penetration of blood-brain barrier

Brain Research

Volumn 1116, Issue 1, 2006, Pages 215-221

  Banks, William A ^a   Niehoff, Michael L ^a   Drago, Denise ^b   Zatta, Paolo ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Aluminum; Alzheimer's disease; Amyloid beta protein; Blood brain barrier; Neurotoxicity; Peptide

Indexed keywords

ALUMINUM DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42];

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; ENDOTHELIUM CELL; IODINATION; MALE; MEMBRANE PERMEABILITY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; THALAMUS;

ALGORITHMS; ALUMINUM; AMINO ACIDS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; HALF-LIFE; HUMANS; KINETICS; MICE; MICE, INBRED ICR; REGRESSION ANALYSIS;

EID: 33749425248     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.07.112     Document Type: Article

References (64)

1. Ajaya B., and Haranath P.S. Effects of insulin administered into cerebrospinal fluid spaces on blood glucose in unanaesthetized and anaesthestized dogs. Indian J. Med. Res. 75 (1982) 607-615
2. Alfrey A.C., Mishell J.M., and Burks J. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans.-Am. Soc. Artif. Intern. Organs 18 (1972) 257-261
3. Allen D.D., and Yokel R.A. Dissimilar aluminum and gallium permeation of the blood-brain barrier demonstrated by in vivo microdialysis. J. Neurochem. 58 (1992) 903-908
4. Audus K.L., Holthaus S.R., Van Bree J.B.M.M., and Shinogle J.A. Aluminum effects on growth of brain microvessel endothelial cells in primary culture. Res. Commun. Chem. Pathol. Pharmacol. 60 (1988) 71-85
5. Bading J.R., Yamada S., Mackic J.B., Kirkman L., Miller C., Calero M., Ghiso J., Frangione B., and Zlokovic B.V. Brain clearance of Alzheimer's amyloid-β040 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J. Drug Target. 10 (2002) 359-368
6. Banks W.A., and Kastin A.J. Aluminum alters the permeability of the blood-brain barrier to some non-peptides. Neuropharmacology 24 (1985) 407-412
7. Banks W.A., Kastin A.J., and Fasold M.B. Differential effect of aluminum on the blood-brain barrier transport of peptides, technetium and albumin. J. Pharmacol. Exp. Ther. 244 (1988) 579-585
8. 1-40 by murine and human intracellular enzymes. Neurotoxicol. Teratol. 18 (1996) 671-677
9. Banks, W.A., Kastin, A.J., Maness, L.M., Banks, M.F., Shayo, M., 1997. Interactions of β-amyloids with the blood-brain barrier. de la Torre, J. C. and Hachinski, V. [826], 190-199. New York, NY, Ann. N.Y. Acad. Sci.
10. Banks W.A., Fasold M.B., and Kastin A.J. Measurement of efflux rate from brain to blood. In: Irvine G.B., and Williams C.H. (Eds). Methods in Molecular Biology: Neuropeptides Protocols (1997), Humana Press, Totowa, NJ 353-360
11. Banks W.A., Robinson S.M., Verma S., and Morley J.E. Efflux of human and mouse amyloid β proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 121 (2003) 487-492
12. Bugiani O., and Ghetti B. Progressing encephalomyelopathy with muscular atrophy, induced by aluminum powder. Neurobiol. Aging 3 (1982) 209-222
13. Bush A.I., and Tanzi R.E. The galvanization of beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2006) 7179-7317
14. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radical Biol. Med. 32 (2002) 1050-1060
15. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
16. Cannata J.B., Fernandez-Soto I., Fernandez-Menendez M.J., Fernandez-Martin J.L., McGregor S.J., Brock J.H., and Halls D. Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int. 39 (1991) 799-803
17. Cashion M.F., Banks W.A., and Kastin A.J. Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-α. Horm. Behav. 30 (1996) 280-286
18. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
19. Crapper D.C., and Dalton A.J. Aluminum induced neurofibrillary degeneration, brain electrical activity and alterations in acquisition and retention. Physiol. Behav. 10 (1973) 935-945
20. Deane R., Yan S.D., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 7 (2003) 907-913
21. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., and Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 (2004) 333-344
22. Deloncle R., and Guillard O. Mechanism of Alzheimer's disease: arguments for a neurotransmitter-aluminium complex implication. Neurochem. Res. 15 (1990) 1239-1245
23. Drago, D., Folin, M., Baiguera, S., Tognon, G., Fernanda, R., Zatta, P., in press. Comparative effects of Aβ(1-42)-Al complex from rat and human amyloid on rat endothelial cell cultures. J. Alzheimers Disease.
24. 14C]sucrose in rats. Brain Res. 569 (1992) 330-335
25. Fonfria E., Marshall I.C., Boyfield I., Skaper S.D., Hughes J.P., Owen D.E., Zhang W., Miller B.A., Benham C.D., and McNulty S. Amyloid beta-peptide (1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J. Neurochem. 95 (2005) 715-723
26. Ghersi-Egea J.F., Gorevic P.D., Ghiso J., Frangione B., Patlak C.S., and Fenstermacher J.D. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67 (1996) 880-883
27. Gilman S., Koeppe R.A., Little R., An H., Junck L., Giordani B., Persad C., Heumann M., and Wernette K. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann. Neurol. 55 (2004) 774-780
28. 3H]dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
29. Gold G. Vascular dementia: a diagnostic challenge. Psychogeriatrics 15 (2003) 111-114
30. Greenblatt D.J., and Koch-Weser J. Clinical pharmacokinetics. N. Engl. J. Med. 293 (1975) 702-705
31. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
32. Huang X., Moir R.D., Tanzi R.E., Bush A.I., and Rogers J.T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1012 (2004) 153-163
33. Humpel C., and Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease. Curr. Neurovasc. Res. 2 (2003) 269-270
34. Jakovljevic V., Banic B., and Radunovic A. The effect of aluminium chloride upon the transition of drugs through the blood-brain barrier into the central nervous system. Eur. J. Drug Metab. Pharmacokinet. 16 (1991) 171-175
35. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 109 (2002) 813-836
36. Jellinger K.A. Understanding the pathology of vascular cognitive impairment. J. Neurol. Sci. 229-230 (2005) 57-63
37. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J. Alzheimer's Dis. 8 (2005) 171-182
38. 14C]sucrose. Brain Res. 377 (1986) 286-291
39. Kurz A., Riemenschneider M., and Vallin A. Potential biological markers for cerebrovascular disease. Psychogeriatrics 15 (2003) 89-97
40. Maness L.M., Banks W.A., Podlisny M.B., Selkoe D.J., and Kastin A.J. Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier. Life Sci. 21 (1994) 1643-1650
41. Mantyh P.W., Ghilardi J.R., Rogers S., DeMaster E., Allen C.J., Stimson E.R., and Maggio J.E. Aluminum, iron, and zinc ions promote aggregation of physiological concentration of β-amyloid peptide. J. Neurochem. 61 (1993) 1171-1174
42. Martyn C.N., Osmond C., Edwardson J.A., Barker D.J.P., Harris E.C., and Lacey R.F. Geographical relation between Alzheimer's disease and aluminium in drinking water. Lancet I (1989) 59-62
43. Metal ions and neurodegenerative disorders. J. Alzheimer's Dis. 8 2 (2005) 90-206
44. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye G.D., Kilts C.A., Beaumont K., Breese G.R., and Prange A.J. Interaction of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225 (1983) 337-345
45. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., Dewachter I., Banks W.A., Van Leuven F., and Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16 (2002) 860-862
46. Pratico D., Uryu K., Sung S., Tang S., Trojanowski J.Q., and Lee V.M. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 17 (2002) 1138-1140
47. Rabe A., Lee M.H., Shek J., and Wisniewski H.M. Learning deficit in immature rabbits with aluminum-induced neurofibrillary changes. Exp. Neurol. 76 (1982) 441-446
48. Rhodin J.A., Thomas T.N., Clark L., Garces A., and Bryant M. In vivo cerebrovascular actions of amyloid beta-peptides and the protective effect of conjugated estrogens. J. Alzheimer's Dis. 5 (2003) 275-286
49. Ricchelli F., Drago D., Filippi B., Tognon G., and Zatta P. Aluminum-triggered structural modifications and aggregation of β-amyloids. A comparison with copper and zinc. Cell. Mol. Life Sci. 62 (2005) 1724-1733
50. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
51. Shin R.W., Lee V.M., and Trojanowski J.Q. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. J. Neurosci. 14 (1994) 7221-7233
52. Shin R.W., Lee V.M., and Trojanowski J.Q. Neurofibrillary pathology and aluminum in Alzheimer's disease. Histol. Histopathol. 10 (1995) 969-978
53. Tanzi R.E., Moir R.D., and Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43 (2004) 608
54. Varadarajan S., Yatin S., Aksenova M., and Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130 (2000) 184-208
55. Xu Z.C., Tang J.P., Xu Z.X., and Melethil S. Kinetics of aluminum in rats IV: blood and cerebrospinal fluid kinetics. Toxicol. Lett. 63 (1992) 7-12
56. Yatin S.M., Varadarajan S., Link C.D., and Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-43). Neurobiol. Aging 20 (1999) 325-330
57. 26Al exposure. Toxicol. Sci. 64 (2001) 77-82
58. Zatta P. Aluminum (III) as a promoter of cellular oxidation. Coord. Chem. Rev. 228 (2002) 285-296
59. Zatta P., Zambenedetti P., Bruna V., and Filippi B. Activation of acetylcholinesterase by aluminium(III): the relevance of the metal species. NeuroReport 5 (1994) 1777-1780
60. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89 (2004) 807-811
61. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208
62. Zlokovic B.V., Ghiso J., Mackic J.B., McComb J.G., Weiss M.H., and Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem. Biophys. Res. Commun. 197 (1993) 1034-1040
63. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., Frangione B., and Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4229-4234
64. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., and Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism?. Nat. Med. 6 (2000) 718-719